MetricSide LogoMetricSide
Learn
  1. Home
  2. Companies
  3. Healthcare
  4. PNTG
OverviewMetricsPricesRevenue & ProfitAssets & LiabilitiesCash FlowMarginsPrice RatiosOthers
MetricSide

Standardized stock fundamentals and valuation metrics. Analyze revenue, EBITDA, free cash flow, and more with interactive charts.

Stock Sectors

  • Technology
  • Healthcare
  • Financials
  • Consumer
  • Industrials
  • Energy
  • Real Estate
  • Materials

Legal & Contact

  • Terms of Service
  • Privacy Policy
  • Contact Us
Not Financial Advice: MetricSide is a data aggregation and visualization tool. Nothing on this website constitutes investment advice, a recommendation, or a solicitation to buy or sell any security. All data is provided for informational and educational purposes only. Past performance is not indicative of future results. Always consult a qualified financial professional before making investment decisions. Data accuracy is not guaranteed — verify critical information against official sources.

© 2026 MetricSide. All rights reserved.

The Pennant Group (PNTG) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

The Pennant Group
NasdaqGS•Healthcare•Medical Care Facilities
$38.00-0.54(-0.01%)Market closed
Market Cap
$1.39B
P/E
43.1x
P/S
1.3x
P/B
3.4x

The Pennant Group, Inc. provides healthcare services in the United States. It operates in two segments, Home Health and Hospice Services, and Senior Living Services. The company offers home health services, including clinical services, such as nursing, speech, occupational and physical therapy, medical social work, and home health aide services; and hospice services comprising clinical care, education, and counseling services for the physical, spiritual, and psychosocial needs of terminally ill patients and their families. It also provides senior living services, such as residential accommodations, activities, meals, housekeeping, and assistance in the activities of daily living to seniors who are independent or who require some support. The company operates home health, hospice, and home care agencies, as well as senior living communities in Alabama, Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Tennessee, Texas, Utah, Washington, Wisconsin, and Wyoming. The Company was incorporated in 2019 and is headquartered in Eagle, Idaho.

B

How this company scores

GoodMetricSide Score: 68/100

Strongest: Growth (22/25); weakest: Profitability (9/25).

Profitability9/25
Growth22/25
Balance Sheet & Red Flags16/25
Cash & Earnings Quality21/25
Strengths
Growing revenueRising earningsLow leverageCash-backed earnings

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 43.1x5y range 26.6x – 309.5x
P/E 43.1x · near its 19-quarter median

Currently near its 19-quarter median.

P/S · 1.3x5y range 0.6x – 1.9x
P/S 1.3x · near its 20-quarter median

Currently near its 20-quarter median.

P/B · 3.4x5y range 2.4x – 7.4x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Leverage Risk

Watch

Debt-to-equity has risen 329.2% recently — increasing financial risk even if the current ratio is manageable.

Cash Burn

Watch

FCF turned negative in 2 of the last 8 quarters — occasional cash consumption.

Price & Volume
Market Cap $1.39B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue
$1.10B
7Q
Q. Revenue
$297.98M
36%
TTM EBITDA
$72.34M
7Q
TTM Op. Income
$62.20M
3Q
Q. Op. Income
$17.19M
2Q
TTM Net Income
$32.32M
3Q
Q. Net Income
$9.08M
28%
EPS
$0.26
3Q
Shares Out.
$34.84M
7Q
$1.10B in TTM revenue grew 37.9% YoY, reaching $297.98M last quarter. TTM EBITDA of $72.34M and TTM operating income of $62.20M show growth is flowing through to the bottom line. TTM net income of $32.32M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin
18.6%
2Q
EBITDA Margin
6.8%
9%
Op. Margin
5.8%
10%
Net Margin
3.0%
3Q
Op. margin of 5.8% is up 0.5% YoY — cost efficiency is improving. Net margin at 3.0% and gross margin of 18.6% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 10% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio
43.1x
3Q
P/S Ratio
1.3x
2%
P/B Ratio
3.4x
3Q
At 43.1x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 1.3x and P/B of 3.4x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Across the last 8 quarters, P/E has risen for 3 consecutive quarters — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets
$1.04B
38%
Cash
$15.27M
6%
Long-Term Debt
$192.50M
420%
Book Value
$404.44M
7Q
D/E Ratio
0.5
329%
Debt/EBITDA
9.5
252%
With $1.04B in assets and $192.50M in long-term debt, D/E is 0.5and book value is $404.44M — a conservative capital structure with a cushion to weather downturns. Over the past year, debt/equity is up 329% — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow
$21.83M
37%
TTM Free Cash Flow
$34.68M
7%
FCF Margin
3.1%
22%
FCF / Net Income
1.1
11%
TTM FCF of $34.68M on $21.83M in operating cash flow. The FCF / Net Income ratio of 1.1x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 7% — a weakening trend.

Related Stocks in Healthcare

View Sector
LLY$938.28B
Lilly (Eli)
Drug Manufacturers - General
JNJ$586.47B
Johnson & Johnson
Drug Manufacturers - General
ABBV$411.57B
AbbVie
Drug Manufacturers - General
MRK$303.29B
Merck & Co.
Drug Manufacturers - General
UNH$249.74B
UnitedHealth Group
Healthcare Plans
TMO$203.77B
Thermo Fisher Scientific
Diagnostics & Research
AMGN$201.34B
Amgen
Drug Manufacturers - General
GILD$191.61B
Gilead Sciences
Drug Manufacturers - General
P/B 3.4x
· near its 20-quarter median

Currently near its 20-quarter median.

Share Dilution

Red Flag

Shares outstanding increased 15.0% — significant dilution, likely from stock compensation or capital raises.